Safety and Immunogenicity of a PHH-1V Booster Dose after Different Prime Vaccination Schemes against Covid-19: Phase III Clinical Trial Final Results Up To One Year. acbr. 2024;8(4):326-342. Accessed October 23, 2026. https://www.fortunejournals.org/ojs/index.php/acbr/article/view/15082